SITE001-0157

SITE001 (USA) › SITE001-0157

SITE001-0157

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2026-03-03

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-05 (study day 50); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-29 (study day 43); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.